Literature DB >> 12517365

Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs.

Janyce F Rogers1, Anne N Nafziger, Joseph S Bertino.   

Abstract

Drug-metabolizing enzyme activity is one of many factors affecting patient response to medications. The objective of this review is to highlight the potential for genetic variability in cytochrome P450 enzyme activity that can lead to interperson differences in response to drugs. Awareness and application of this knowledge will improve drug use in clinical practice and provide the physician with further appreciation that standard drug dosing may not be appropriate in all patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12517365     DOI: 10.1016/s0002-9343(02)01363-3

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  36 in total

1.  Allele and genotype frequency of CYP2C9 in Tamilnadu population.

Authors:  C Adithan; N Gerard; S Vasu; R Balakrishnan; C H Shashindran; R Krishnamoorthy
Journal:  Eur J Clin Pharmacol       Date:  2003-09-19       Impact factor: 2.953

2.  The κ-opioid receptor gene as a predictor of response in a cocaine vaccine clinical trial.

Authors:  David A Nielsen; Sara C Hamon; Thomas R Kosten
Journal:  Psychiatr Genet       Date:  2013-12       Impact factor: 2.458

3.  Dermatology in the postgenomic era: harnessing human variation for personalized medicine.

Authors:  Anthony E Oro
Journal:  Arch Dermatol       Date:  2008-03

Review 4.  Pharmacogenetic treatments for drug addiction: cocaine, amphetamine and methamphetamine.

Authors:  Colin N Haile; Thomas R Kosten; Therese A Kosten
Journal:  Am J Drug Alcohol Abuse       Date:  2009       Impact factor: 3.829

5.  Toxicogenetics--cytochrome P450 microarray analysis in forensic cases focusing on morphine/codeine and diazepam.

Authors:  H Andresen; C Augustin; T Streichert
Journal:  Int J Legal Med       Date:  2012-08-17       Impact factor: 2.686

6.  Impact of age, CYP2C9 genotype and concomitant medication on the rate of rise for prothrombin time during the first 30 days of warfarin therapy.

Authors:  Russell A Wilke; Richard L Berg; Humberto J Vidaillet; Michael D Caldwell; James K Burmester; Michael A Hillman
Journal:  Clin Med Res       Date:  2005-11

7.  An inservice program on pharmacogenetics to individualize drug therapy.

Authors:  Tracy Zembles
Journal:  Am J Pharm Educ       Date:  2010-02-10       Impact factor: 2.047

8.  DBH gene as predictor of response in a cocaine vaccine clinical trial.

Authors:  Thomas R Kosten; Coreen B Domingo; Sara C Hamon; David A Nielsen
Journal:  Neurosci Lett       Date:  2013-02-28       Impact factor: 3.046

Review 9.  Pain treatment with opioids : achieving the minimal effective and the minimal interacting dose.

Authors:  Pierangelo Geppetti; Silvia Benemei
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

10.  Pharmacogenetic randomized trial for cocaine abuse: disulfiram and dopamine β-hydroxylase.

Authors:  Thomas R Kosten; Guiying Wu; Wen Huang; Mark J Harding; Sara C Hamon; Jaakko Lappalainen; David A Nielsen
Journal:  Biol Psychiatry       Date:  2012-08-18       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.